Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 chhip trial

Three-year safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized alpharadin in symptomatic prostate cancer trial

Updated analysis of the phase iii, double- blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (crpc) patients with bone metastases (alsympca)

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 chhip trial

Outcome and patient-reported toxicity in localised prostate cancer treated with dose-escalated hypofractionated intensity-modulated radiotherapy

Dose-escalated hypofractionated intensity-modulated radiotherapy in high-risk carcinoma of the prostate: outcome and late toxicity

Pd-0178: parameterised rectal dose and associations with latetoxicity in high-dose-rate prostate brachytherapy

Ep-1223: endorectal balloons in prostate cancer radiotherapy: effects on seminal vesicle positioning

Alpha emitter radium-223 and survival in metastatic prostate cancer